











































Differentiating cervical pre-cancer from invasive cancer from
invasive cancer with the S5 DNA methylation classifier
Citation for published version:
Banila, C, Belinda, N, Kleeman, M, Reuter, C, Cuschieri, K, Clifford, G, Cuzick, J & Lorincz , A 2018,
'Differentiating cervical pre-cancer from invasive cancer from invasive cancer with the S5 DNA methylation
classifier', EUROGIN 2018 - From control to elimination of HPV induced cancers, Lisbon, Portugal, 2/12/18 -
5/12/18. https://doi.org/https://www.eurogin.com/2018/images/pdf/Abstratcs-Part2.pdf
Digital Object Identifier (DOI):
https://www.eurogin.com/2018/images/pdf/Abstratcs-Part2.pdf
Link:
Link to publication record in Edinburgh Research Explorer
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
 326/490 
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Background / Objectives 
Background: Persistent infection with high-risk human papillomavirus (hr-HPV) is an 
important co-factor in cervical cancer development and is associated with DNA 
methylation on both human and viral genes. The S5 DNA methylation classifier, 
based on target CpG sites of the human gene EPB41L3, and viral late gene regions 
of HPV16, HPV18, HPV31 and HPV33 (Lorincz A et al., 2016) has demonstrated 
better performance for detection of CIN2/3 women than either HPV16/18 genotyping, 
cytology or combination. We tested the performance of S5 in detecting invasive 
cancers versus pre-cancers and quantified the degree of separation between 




Methods: Methylation status of the S5 selected CpG sites was tested in DNA 
extracted from formalin-fixed biopsies from the Scottish HPV Archive (UK, n=24) and 
PreservCyt collected exfoliated cervical cell samples from the Scottish HPV Archive 
(UK, n=48) and the International Agency for Research on Cancer (Spain, n=100). 
Samples were histologically defined as negative/CIN1 (n=33), CIN2/3 (n=65) and 
invasive cancer (n=74). DNA bisulfite conversion was carried out and followed by 
pyrosequencing for the 6 components of S5. Average methylation was calculated for 
each marker to define the S5 score. 
 
Conclusion 
Results: Methylation at all sites increased proportionally with disease severity with a 
Cuzick trend value of z = 9.2933 (p < 2.2x10-16). The separation of normal/CIN1 
from CIN2/3 and from cancer was highly significant (Mann Whitney test, both p < 
0.0001). S5 also showed highly significant difference between CIN2/3 and invasive 
 327/490 
cancer from both IARC-Spain (p < 0.0001) and Scottish (p < 0.003) cohorts. Receiver 
operating characteristic (ROC) curves were used to assess the diagnostic potential of 
S5 in differentiating cancers from CIN2/3. The area under the ROC curve (AUC) was 
0.86 (CI 95%: 0.7965 to 0.9131, p < 0.0001) with a sensitivity of 79.8% and a 
specificity of 83.1%, based on a cut-off at highest Youden J index. 
References 
Conclusion: The S5 methylation classifier may be useful in cervical screening 
programs for differentiating pre-cancers from invasive cervical cancers in women 
infected with hr-HPV. Although the separation was very good, there is room for 
improvement in S5 by addition of new markers derived from an ongoing multi-omics 
study using next-Generation Sequencing. 
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